|
|
|
Stem Cell Related Patent Number US5843435
| Title: | Immunotherapy of cancer with allogeneic lymphocytes | | Inventors: | Slavin, Shimon; Jerusalem, Israel | | Summary: | Described herein is a method of treating a human cancer patient having malignant breast cancer cells, after the patient has received a malignant cell debulking procedure followed by an autologous stem cell transplantation procedure. This invention addresses the problem of disease relapse which often occurs due to a population of residual malignant breast cancer cells that may remain viable in a patient following a debulking procedure. Methods of the invention include an infusion with allogeneic peripheral blood lymphocytes, either alone or in combination with in vivo or in vitro T-cell activation, which is administered following partial hematopoiesis recovery. Therapeutic applications include the use of such infused allogeneic lymphocytes for purposes of engendering an anti-malignant cell response in such cancer patients. | | Abstract: | Methods have been discovered for treating residual disease following removal of most or a substantial fraction of malignant cells from a cancer patient. An autologous stem cell transplant is performed on the patient. Following partial hematopoiesis recovery, the patient is infused with allogeneic peripheral blood lymphocytes, either alone or in combination with in vivo or in vitro T-cell activation. The infused allogeneic lymphocytes engender and anti-malignant cell response. | | US Patent Website: | Click Here for Full Text of Patent | | Title Number: | US5843435 | | Application Number: | US1996000714144 | | Date Filed: | 16/09/1996 | | Date Published: | 01/12/1998 | | Assignee: | Hadasit Medical Research Services and Development Ltd., Jerusalem, Israel
Baxter International Inc., Deerfield, IL, USA |
|
|
